ArticleCureus2026
Off-Label Use of Gabapentinoids in Non-diabetic Patients Referred to a Rheumatology Clinic: A Cross-Sectional Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gabapentin is FDA-approved for postherpetic neuralgia and partial-onset seizures, while pregabalin is approved for several neuropathic pain conditions, fibromyalgia, and as adjunctive therapy for partial-onset seizures. Despite limited evidence for many off-label uses, gabapentinoids are frequently prescribed, raising concerns about adverse effects, misuse, and dependence. This study examines gabapentinoid prescribing patterns among patients referred to our rheumatology clinic. Patients and methods A cross-sectional study of patients without diabetes (N=466) was conducted among newly referred patients to our rheumatology clinic. Data was extracted from the electronic medical records system and recorded in the REDCap database. Patients' presenting complaints, comorbid conditions, and current medications were analyzed. Descriptive analyses were performed, and statistical analyses were conducted using a t-test for continuous variables, a chi-square test for categorical variables, and effect sizes were reported as odds ratios (OR). Key results Our findings reveal that 17.8% of patients referred to our clinic were prescribed gabapentinoids, many of whom also received concomitant prescriptions for opioids, including tramadol (34%), and antidepressants (32.5 %). Gabapentinoid use was more prevalent among patients with depression (OR=4.51) and anxiety (OR=3.69). Additionally, patients presenting with back pain (OR=3.78) and fatigue (OR=1.75) were more likely to be taking gabapentinoids. In contrast, symptoms such as multiple joint pain, dry eyes, and dry mouth showed no significant difference. Conclusion Our study provides insight into prescribing practices of gabapentinoids within the rheumatology setting. About one-third of the patients on gabapentinoids were also taking other medications with greater potential for harm with concomitant use. Evidence supporting the efficacy of gabapentinoids in different medical conditions is needed to guide clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.